Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application.
A nonionic surfactant MEKC method with LIF detection was developed for the simultaneous determination of memantine, an anti-Alzheimer's disease agent, and amantadine, an anti-Parkinson's disease drug, in human plasma. Before analysis, the plasma samples were pretreated by liquid-liquid extraction with ethyl acetate, and derivatized with 6-carboxyfluorescein N-hydroxysuccinimide ester. The chemical derivatization is performed with 6-carboxyfluorescein N-hydroxysuccinimide ester in ACN - 5 mM pH 9.0 borate buffer (40:60, v/v) at 35 degrees C for 3 h. After the derivatization reaction, hydrodynamic injection (0.5 psi, 8 s) was used to introduce the derivatized solution, and the separation was performed in borate buffer (30 mM, pH 9.5) with the nonionic surfactant Brij-35 (0.07%, w/v); the separation voltage was 6 kV. The linear ranges of the method for the determination of memantine and amantadine in human plasma were over a range of 2.0-60.0 ng/mL. The detection limit was 0.5 ng/mL (S/N=3). This method was applied successfully to monitor the concentration of memantine or amantadine in patients with Alzheimer's disease or Parkinson's disease.
Yeh
Hsin-Hua
HH
School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yang
Yuan-Han
YH
Chen
Su-Hwei
SH
D000097:Acetonitriles; D000544:Alzheimer Disease / Q000097:blood / Q000188:drug therapy; D000547:Amantadine / Q000097:blood* / Q000737:chemistry / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000097:blood* / Q000737:chemistry / Q000627:therapeutic use; D005591:Chemical Fractionation; D020374:Chromatography, Micellar Electrokinetic Capillary / Q000379:methods*; D005452:Fluoresceins / Q000032:analysis* / Q000737:chemistry; D006801:Humans; D006863:Hydrogen-Ion Concentration; D016014:Linear Models; D008559:Memantine / Q000097:blood* / Q000737:chemistry / Q000627:therapeutic use; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence / Q000379:methods*; D013388:Succinimides / Q000737:chemistry
C087165:5-(6)-carboxyfluorescein diacetate succinimidyl ester; D000097:Acetonitriles; D000978:Antiparkinson Agents; D005452:Fluoresceins; D013388:Succinimides; D000547:Amantadine; D008559:Memantine; C032159:acetonitrile